pCR Plasmids
pCR plasmids are specialized cloning vectors designed for efficient cloning of PCR products. These vectors are part of the TA (Taq polymerase-based) cloning system and are specifically engineered to simplify the ligation and propagation of DNA fragments generated by PCR. The vectors utilize the single 3′-adenine (A) overhangs added by Taq polymerase to ligate into complementary 3′-thymine (T) overhangs on the plasmid.
Key Features of pCR Plasmids
- 3′-T Overhangs:
- Pre-linearized plasmids with single 3′-thymine overhangs on both ends, facilitating direct ligation of PCR products with complementary 3′-A overhangs.
- Promoter Sites:
- Typically include dual promoters, such as T7 and SP6, flanking the cloning site for in vitro RNA transcription or bidirectional sequencing.
- Selectable Markers:
- Ampicillin Resistance (ampR) or Kanamycin Resistance (kanR): Provides antibiotic resistance for selection in E. coli.
- LacZα Fragment: Allows blue-white screening for identifying recombinant colonies on X-gal/IPTG plates.
- Multiple Cloning Site (MCS):
- Contains restriction sites for downstream manipulation of cloned fragments.
Applications of pCR Plasmids
- PCR Product Cloning:
- Designed for direct ligation of PCR-amplified DNA fragments without additional modification steps.
- Blue-White Screening:
- Simplifies identification of recombinant colonies using lacZα-based color screening.
- Sequencing:
- Used for sequencing PCR products due to the universal primer-binding sites flanking the cloning region.
- Subcloning:
- Serve as intermediate vectors for transferring PCR products to other specialized vectors for expression, mutagenesis, or functional studies.
pCR plasmids are versatile and efficient tools for cloning PCR products, providing seamless integration into workflows involving sequencing, subcloning, and RNA synthesis. Their unique 3′-T overhangs, combined with features like blue-white screening and high-copy-number replication, make them indispensable in molecular biology research.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|